Search

Your search keyword '"Delmee, M."' showing total 4 results
Start Over Author "Delmee, M." Publisher elsevier b.v.
4 results on '"Delmee, M."'

2. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes

Author

Freeman, J., Vernon, J., Morris, K., Nicholson, S., Todhunter, S., Longshaw, C., Wilcox, M. H., Pfeiffer, S., Delmee, M., Muytjens, L., Broeck, J. V., Ivanova, K., Maikanti-Charalampous, P., Nyc, O., Engberg, J., Barbut, F., Marchandin, H., Jean-Pierre, H., Muller, L. V., Mutters, R., Schubert, S., Bader, J., Malamou-Lada, E., Orfanidou, M., Smilakou, S., Nagy, E., Urban, E., Barna, Z., Kristoff, K., Fitzpatrick, F., Skally, M., Fenelon, L., Dennehy, F., Mastrantonio, P., Farina, C., Sanguinetti, M., Masucci, L., Zaccaria, T., Barbui, A., Gesu, G., Sironi, M. C., Balode, A., Pituch, H., Oleastro, M., Novakova, E., Rupnik, M., Bouza, E., Reigadas, H., Alcala, L., Linares, J., Njubo, J., Tubau, F., Noren, T., Widmer, A., Frei, R., Altwegg, M., Kuijper, E., Harmanus, C., Fairley, D., Morris, T., Crook, D., Griffiths, D., Planche, T., Monahan, I., Coia, J., Mather, H., Farina C., Sanguinetti M. (ORCID:0000-0002-9780-7059), Masucci L. (ORCID:0000-0002-8358-6726), Freeman, J., Vernon, J., Morris, K., Nicholson, S., Todhunter, S., Longshaw, C., Wilcox, M. H., Pfeiffer, S., Delmee, M., Muytjens, L., Broeck, J. V., Ivanova, K., Maikanti-Charalampous, P., Nyc, O., Engberg, J., Barbut, F., Marchandin, H., Jean-Pierre, H., Muller, L. V., Mutters, R., Schubert, S., Bader, J., Malamou-Lada, E., Orfanidou, M., Smilakou, S., Nagy, E., Urban, E., Barna, Z., Kristoff, K., Fitzpatrick, F., Skally, M., Fenelon, L., Dennehy, F., Mastrantonio, P., Farina, C., Sanguinetti, M., Masucci, L., Zaccaria, T., Barbui, A., Gesu, G., Sironi, M. C., Balode, A., Pituch, H., Oleastro, M., Novakova, E., Rupnik, M., Bouza, E., Reigadas, H., Alcala, L., Linares, J., Njubo, J., Tubau, F., Noren, T., Widmer, A., Frei, R., Altwegg, M., Kuijper, E., Harmanus, C., Fairley, D., Morris, T., Crook, D., Griffiths, D., Planche, T., Monahan, I., Coia, J., Mather, H., Farina C., Sanguinetti M. (ORCID:0000-0002-9780-7059), and Masucci L. (ORCID:0000-0002-8358-6726)

Abstract

Clostridium difficile infection remains a major healthcare burden. Until the recent introduction of fidaxomicin, antimicrobial treatments were limited to metronidazole and vancomycin. The emergence of epidemic C.difficile PCR ribotype 027 and its potential link to decreased antibiotic susceptibility highlight the lack of large-scale antimicrobial susceptibility and epidemiological data available. We report results of epidemiological and antimicrobial susceptibility investigations of C.difficile isolates collected prior to fidaxomicin introduction, establishing important baseline data. Thirty-nine sites in 22 countries submitted a total of 953 C.difficile isolates for PCR ribotyping, toxin testing, and susceptibility testing to metronidazole, vancomycin, fidaxomicin, rifampicin, moxifloxacin, clindamycin, imipenem, chloramphenicol, and tigecycline. Ninety-nine known ribotypes were identified. Ribotypes 027, 014, 001/072, and 078 were most frequently isolated in line with previous European studies. There was no evidence of resistance to fidaxomicin, and reduced susceptibility to metronidazole and vancomycin was also scarce. Rifampicin, moxifloxacin, and clindamycin resistance (13%, 40%, and 50% of total isolates, respectively) were evident in multiple ribotypes. There was a significant correlation between lack of ribotype diversity and greater antimicrobial resistance (measured by cumulative resistance score). Well-known epidemic ribotypes 027 and 001/072 were associated with multiple antimicrobial resistance, but high levels of resistance were also observed, particularly in 018 and closely related emergent ribotype 356 in Italy. This raises the possibility of antimicrobial exposure as the underlying reason for their appearance, and highlights the need for ongoing epidemiological and antimicrobial resistance surveillance.

Published
2015

4. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays.

Author

André, E., Goeminne, L., Colmant, A., Beckert, P., Niemann, S., and Delmee, M.

Subjects
*MYCOBACTERIOSIS, *MYCOBACTERIUM, *MYCOBACTERIAL diseases, *TUBERCULOSIS, *RIFAMPIN
Abstract

Objectives Neither the liquid medium-based Bactec MGIT, nor commercial molecular assays such as the Xpert MTB/RIF and the MTBDR plus V2.0 assays are capable of detecting up to 30% of rifampicin-resistant Mycobacterium tuberculosis strains in Swaziland because of the large proportion of the rpoB Ile491Phe mutations. In other countries, the frequency of this mutation is thought to be low. Methods We designed a real-time multiplex allele-specific PCR assay to identify the rpoB Ile491Phe mutation responsible for these undetected resistant M. tuberculosis strains. Results The technique showed 100% similarity with rpoB sequencing on a panel of 78 strains from Swaziland. Conclusions We propose that the detection of the rpoB Ile491Phe rpoB mutation should complement commercial assays for the diagnosis of rifampicin-resistant M. tuberculosis in routine conditions, particularly in countries where this specific mutation is frequent. The technique proposed in this paper is adapted for most reference laboratories. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results